Announcements Trials
Browse Landscape

Phase

Phase 1 38Phase 3 31Phase 2 31Phase 1/2 26Phase 2/3 2Phase 4 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 17NIH 5NETWORK 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9anlotinib 7Trastuzumab 7Injections 7Rituximab 6atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5venetoclax 4Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Albumin-Bound Paclitaxel 4sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Cytarabine × Clear all
NCT06788756 2026-04-29

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Moleculin Biotech, Inc.

Phase 2/3 Recruiting
312 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07255872 2026-03-05

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
216 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡